Skip to main content
    C

    Coya Therapeutics, Inc. Common Stock (COYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    -0.13 (-4.15%)

    Market Cap: $73.42M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Coya Therapeutics, Inc. Common Stock (COYA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Coya Therapeutics, Inc. Common Stock reported revenue of $7.95M for the fiscal year ended Dec 31, 2025, up 123.6% from the year before. That year, net income was -$21.23M with a net margin of -267.1%, operating cash flow was -$10.74M and free cash flow was -$10.74M. The quarter ended Sep 30, 2026 had revenue of $234.13K and net income of -$10.62M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$7.95M+123.6%100.0%-283.9%-267.1%
    Dec 2024$3.55M-40.8%100.0%-485.4%-418.7%
    Dec 2023$6.00MN/A100.0%-131.7%-133.1%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$7.95M$3.55M$6.00M$0$0N/A
    Cost of revenue$0$0$0$0$16.13KN/A
    Gross profit$7.95M$3.55M$6.00M$0-$16.13KN/A
    Research and development$19.02M$11.89M$6.04M$4.94M$2.54M$373.45K
    Operating income-$22.56M-$17.25M-$7.90M-$9.81M-$4.87M-$1.04M
    Net income-$21.23M-$14.88M-$7.99M-$12.24M-$4.89M-$1.10M
    EBITDA-$21.20M-$15.57M-$7.24MN/AN/A$10.44K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$234.13K$243.75K$251.15K$3.96M$3.56M$163.62K$257.88K$1.95K$0$3.43M$126.84K$6.00M
    Gross profit$234.13K$243.75K$251.15K$3.96M$3.56M$163.62K$257.88K$1.95K$0$3.43M$126.84K$6.00M
    Operating income-$10.95M-$7.05M-$7.64M-$6.03M-$2.43M-$6.41M-$7.68M-$4.08M-$4.45M-$3.24M-$5.48M$1.82M
    Net income-$10.62M-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M-$2.92M-$4.02M-$2.89M-$5.05M$1.27M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded long-term debt of $0 by $46.82M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$49.95M$44.35M$41.26M$8.40M$4.79M$8.75M
    Current assets$49.94M$44.31M$41.20M$7.18M$4.58M$8.75M
    Cash and equivalents$46.82M$38.34M$32.63M$5.93M$4.34M$8.72M
    Total liabilities$6.92M$4.77M$5.63M$16.79M$1.15M$447.12K
    Short-term debtN/AN/A$723.85KN/AN/AN/A
    Long-term debt$0N/AN/A$12.97MN/AN/A
    Shareholder equity$43.03M$39.58M$35.64M-$8.39M$3.64M$8.30M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$39.32M$47.31M$53.27M$49.95M$32.04M$33.45M$38.40M$44.35M$35.55M$39.94M$37.39M$41.26M
    Total liabilities$5.75M$4.03M$4.30M$6.92M$4.76M$5.14M$5.04M$4.77M$3.54M$4.68M$5.00M$5.63M
    Cash and equivalents$35.80M$43.18M$50.72M$46.82M$28.13M$29.76M$35.53M$38.34M$31.06M$36.58M$35.99M$32.63M
    Shareholder equity$33.57M$43.28M$48.97M$43.03M$27.28M$28.31M$33.37M$39.58M$32.01M$35.26M$32.39M$35.64M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$10.74M-$10.29M-$11.19M-$7.24M-$3.90M-$391.27K
    Capital expenditures$0$0$1$4$136.80K$4
    Free cash flow-$10.74M-$10.29M-$11.19M-$7.24M-$4.04M-$391.27K
    Investing cash flow-$1.16M-$25.00K-$543.19K-$525.00K-$136.80K-$136.80K
    Financing cash flow$20.39M$16.03M$38.43M$9.36M-$340.58K$9.11M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.24M-$7.38M-$6.21M-$1.01M-$1.13M-$5.77M-$2.83M-$2.41M-$5.46M-$4.56M$2.15M-$2.24M
    Capital expendituresN/AN/A$0$3$3$4$50.00K$3$2$3$25.00K$0
    Free cash flowN/AN/A-$6.21M-$1.01M-$1.13M-$5.77M-$2.88M-$2.41M-$5.46M-$4.56M$2.12M-$2.24M
    Last 12 quarters

    Frequently Asked Questions About COYA

    What is Coya Therapeutics, Inc. Common Stock's annual revenue?

    Coya Therapeutics, Inc. Common Stock reported revenue of $7.95M for the fiscal year ended Dec 31, 2025.

    How fast is Coya Therapeutics, Inc. Common Stock's revenue growing?

    Revenue was up 123.6% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Coya Therapeutics, Inc. Common Stock profitable?

    No. Coya Therapeutics, Inc. Common Stock reported net income of -$21.23M for the fiscal year ended Dec 31, 2025, with a net margin of -267.1%.

    How much free cash flow does COYA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.74M minus capital expenditures of $0 produced free cash flow of -$10.74M.

    How much debt does Coya Therapeutics, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0 and cash and equivalents of $46.82M.